INBP · CIK 0001016504
INTEGRATED BIOPHARMA INC
Annual figures as reported, FY2014–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$54.4M
▲ +8.0% vs FY2024
Net income
$808K
▲ +621.4% vs FY2024
Free cash flow
$1.9M
▲ +380.5% vs FY2024
Diluted EPS
$0.03
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Mar ’26 quarter
$10.1M
▼ −27.5% vs Mar ’25
Net income — Mar ’26 quarter
−$837K
▼ −237.0% vs Mar ’25
Revenue — trailing 12 months
$48.3M
▼ −8.8% vs Mar ’25
Diluted EPS — trailing 12 months
−$0.07
▼ −275.0% vs Mar ’25
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Mar ’26 | $10.1M | −27.5% | −2.7% | −$837K | −8.3% | −$0.03 |
| Dec ’25 | $11.3M | −10.6% | 0.3% | −$762K | −6.8% | −$0.03 |
| Sep ’25 | $12.7M | −6.8% | 8.0% | $123K | 1.0% | $0.00 |
| Jun ’25 | $14.2M | 11.2% | 10.4% | −$178K | −1.3% | −$0.01 |
| Mar ’25 | $13.9M | 6.1% | 11.1% | $611K | 4.4% | $0.02 |
| Dec ’24 | $12.6M | 9.6% | 9.3% | $116K | 0.9% | $0.01 |
| Sep ’24 | $13.6M | 5.4% | 10.1% | $259K | 1.9% | $0.01 |
| Jun ’24 | $12.7M | −1.9% | 10.1% | $268K | 2.1% | $0.00 |
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Gross marginOperating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Growth rates
compounding, annualizedRevenue CAGR
−1.1%
3y
+0.6%
5y
+3.8%
10y
Net income CAGR
−40.5%
3y
−27.8%
5y
+1.0%
10y
Diluted EPS CAGR
−37.0%
3y
−25.4%
5y
+4.1%
10y
Free cash flow CAGR
−19.6%
3y
+10.7%
5y
Share count change (split-adjusted)
+0.0%
5y
+6.1%
10y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | FCF margin | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 10.2% | 3.7% | 1.5% | 3.4% | 4.0% | 3.2% | 4.42× | — |
| FY2024 | 7.7% | 0.5% | 0.2% | 0.8% | 0.6% | 0.4% | 2.92× | — |
| FY2023 | 8.0% | 0.2% | −0.1% | 2.2% | −0.2% | −0.1% | 3.39× | 0.00× |
| FY2022 | 11.6% | 4.9% | 6.8% | 6.4% | 20.7% | 15.2% | 3.16× | 0.01× |
| FY2021 | 14.9% | 9.1% | 12.6% | 4.3% | 55.9% | 31.5% | 1.95× | 0.25× |
| FY2020 | 12.7% | 6.2% | 7.8% | 2.1% | 67.7% | 17.9% | 1.26× | 1.38× |
| FY2019 | 12.4% | 5.4% | 3.4% | −0.2% | 89.2% | 8.5% | 1.14× | 5.10× |
| FY2018 | 11.4% | 3.9% | 1.6% | 2.1% | — | 4.7% | 0.76× | — |
| FY2017 | 14.2% | 6.8% | 5.0% | 0.1% | — | 15.4% | 1.13× | — |
| FY2016 | 13.0% | 5.0% | 2.3% | −1.7% | — | 6.9% | 1.02× | — |
| FY2015 | 11.7% | 2.5% | 2.0% | −0.9% | — | 6.3% | 0.79× | — |
| FY2014 | 14.5% | 4.0% | 0.4% | 5.0% | — | 1.1% | 0.79× | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $54.4M | $5.6M | $2.0M | $808K | $0.03 | $2.1M | $191K | $24.9M | $4.6M | $20.3M | $3.6M | — |
| FY2024 | $50.3M | $3.9M | $251K | $112K | $0.00 | $943K | $553K | $26.2M | $7.0M | $19.2M | $1.7M | — |
| FY2023 | $50.7M | $4.1M | $120K | −$34K | $0.00 | $1.2M | $116K | $25.4M | $6.6M | $18.9M | $1.3M | $0 |
| FY2022 | $56.2M | $6.6M | $2.7M | $3.8M | $0.12 | $4.1M | $486K | $25.3M | $6.7M | $18.6M | $331K | $101K |
| FY2021 | $63.6M | $9.5M | $5.8M | $8.0M | $0.25 | $3.0M | $295K | $25.4M | $11.1M | $14.3M | $210K | $3.6M |
| FY2020 | $52.8M | $6.7M | $3.3M | $4.1M | $0.13 | $1.3M | $214K | $22.9M | $16.9M | $6.1M | $402K | $8.3M |
| FY2019 | $50.0M | $6.2M | $2.7M | $1.7M | $0.06 | $328K | $414K | $19.8M | $17.9M | $1.9M | $475K | $9.7M |
| FY2018 | $43.7M | $5.0M | $1.7M | $679K | $0.02 | $1.2M | $247K | $14.6M | $19.8M | −$5.2M | $228K | $9.3M |
| FY2017 | $47.0M | $6.7M | $3.2M | $2.3M | $0.10 | $397K | $327K | $15.2M | $21.1M | −$5.9M | $132K | $10.1M |
| FY2016 | $42.2M | $5.5M | $2.1M | $958K | $0.05 | −$594K | $109K | $13.9M | $22.3M | −$8.3M | $395K | $10.4M |
| FY2015 | $37.5M | $4.4M | $933K | $735K | $0.02 | −$113K | $235K | $11.6M | $20.9M | −$9.3M | $71K | $9.1M |
| FY2014 | $33.7M | $4.9M | $1.4M | $131K | $0.01 | $1.9M | $182K | $11.6M | $21.7M | −$10.2M | $451K | $9.1M |
Latest filings
the most recent regulatory filings8-KFORM 8-K PNC FIRST AMENDMENT2026-07-02 ↗4PRIMARY DOCUMENT2026-06-25 ↗4PRIMARY DOCUMENT2026-06-25 ↗4PRIMARY DOCUMENT2026-06-25 ↗4/APRIMARY DOCUMENT2026-06-25 ↗4PRIMARY DOCUMENT2026-06-25 ↗8-KCurrent report — material event2026-05-08 ↗10-QQuarterly report2026-05-08 ↗SCHEDULE 13DSEC filing2026-04-17 ↗SCHEDULE 13D/ASEC filing2026-04-17 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.